# BPC-157 Reconstitution and Dosing: What the Literature Actually Reports
> Note: PeptIQ is not a medical provider. This article is educational only. It is not a protocol, a prescription, or advice to obtain or administer any compound. Consult a qualified clinician.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a sequence in human gastric juice. Reviews in the gastrointestinal and musculoskeletal literature describe cytoprotective and angiogenic signals in animal models far more often than they describe a settled human dose. That gap is why reconstitution threads and "standard" microgram tables spread so easily. They fill a hole the papers leave open.
This page maps how lyophilized research vials are usually discussed, which figures show up in published work, and what PeptIQ users have logged as observational notes. None of those layers is a protocol.
Evidence tier
| Layer | What it can support | What it cannot |
|---|
| Animal and in vitro papers | Mechanism hypotheses, tissue-specific signals | A human milligram or microgram schedule |
| Sparse human reports | Proof that people have been studied at all | Population dosing or safety |
| Community and in-app logs | What people record, not what works | Medical recommendations |
Sikiric and colleagues have published extensively on gastric pentadecapeptide BPC 157, including a 2018 review framed around gastrointestinal tract applications (PubMed 29569996). Tendon-fibroblast work has reported growth-hormone receptor expression changes in cell culture (PubMed 31058812). Wound-healing reviews continue to appear, still dominated by preclinical models (PubMed 35163351). ClinicalTrials.gov lists BPC-157 studies, but the registry is not a completed human dosing map (ClinicalTrials.gov search).
Human musculoskeletal data remain thin relative to the social-media footprint. Treat any milligram chart as community folklore until a clinician or labeled product says otherwise.
How lyophilized vials are usually discussed
Research-grade BPC-157 is commonly sold as a freeze-dried cake. Until a diluent is added, there is no concentration, only labeled mass. Educational write-ups use the same arithmetic as other lyophilized peptides:
Concentration (mg/mL) = labeled vial milligrams ÷ diluent milliliters
Volume (mL) = desired milligrams ÷ concentration
On a U-100 insulin syringe, 1.0 mL is marked as 100 units. That conversion only holds if the concentration math is correct and the label mass is honest.
Illustrative math, not a protocol
If a vial is labeled 5 mg and someone adds 2 mL bacteriostatic water, the resulting solution is 2.5 mg/mL (2,500 mcg/mL). A 250 mcg draw would be 0.10 mL (10 units). A 500 mcg draw would be 0.20 mL (20 units). Change the water volume and every unit count moves.
Those numbers show how sensitive the syringe reading is to diluent volume. They are not a recommended mix.
Community write-ups typically mention bacteriostatic water rather than sterile water for multi-draw vials, because benzyl alcohol is used as a bacteriostatic preservative. Product-specific instructions, if they exist, outrank forum defaults. Swirl rather than shake is the handling language most educational guides repeat. Refrigeration after reconstitution is the usual storage claim. Beyond-use windows are not standardized across unlabeled research vials.
Research-reference ranges versus community tables
Published BPC-157 work in rodents often uses milligram-per-kilogram intraperitoneal or oral doses that do not translate to a 250 mcg subcutaneous human habit by any validated factor. Chang's tendon-fibroblast paper is a cell-culture exposure study, not a clinic schedule. Sikiric's reviews collect many models and routes. They do not ratify a consumer vial protocol.
What shows up in forums and in PeptIQ logs is a different dataset:
| Source of the number | Typical range people mention | How to read it |
|---|
| Community tables | 250–500 mcg per day, often split | Observational habit, not a trial arm |
| Some clinic education pages | Similar microgram bands, subcutaneous | Practice variation, not FDA labeling |
| Animal papers | mg/kg scales by species and route | Not a human conversion chart |
PeptIQ users who log BPC-157 most often record daily or twice-daily subcutaneous entries in the low-hundreds of micrograms. That is a description of logging behavior. It is not evidence that the range is effective or safe.
Administration route in the literature
Preclinical papers have used oral, intraperitoneal, and local routes depending on the model. Community education almost always discusses subcutaneous administration because that is how research vials are handled in those circles. Route science in animals is not a how-to for a first injection. Technique, site selection, and sterile practice belong with a clinician or a labeled product's instructions for use.
Oral BPC-157 is discussed in gastric-protection papers. That does not mean an unlabeled capsule matches the material in those studies.
What to track if someone is already logging
People who already track BPC-157 in the app tend to record dose, time, site, pain or function scores, and whether another repair peptide is logged the same week. Those fields turn anecdote into a personal time series. They still do not turn a log into a protocol.
Related reading on this site includes the stacking and mixing explainers for BPC-157 with TB-500, plus the 2026 human hamstring and knee-pain snapshots. Those pages cover combination context and early human signals. This page stays on reconstitution math and evidence tiers.
Bottom line
BPC-157 has a large preclinical literature and a small human one. Reconstitution arithmetic is generic lyophilized-peptide math. Dose tables circulating online are community conventions. Published papers do not certify them. Educational use only.
